Anti-Human CD40 In Vivo Antibody – Low Endotoxin (G28.5) [ICH1156]

ichorbio’s anti-CD40 In Vivo Antibody – Low Endotoxin (G28.5) is manufactured in a cGMP compliant, ISO Quality Standard 9001:2015 facility. ichorbio’s low endotoxin antibodies have half the endotoxin of comparable antibodies from our competitors at less than 1.0 EU/mg. If ichorbio’s low endotoxin antibodies are not low enough we also offer ultra low endotoxin antibodies which have even less endotoxin (<0.75EU/mg) at an even higher purity (98% versus 95%). ichorbio: the best antibodies for in vivo research.

CD40

G28.5

ichorbio’s G28.5 in vivo antibody is available in the following bulk sizes:
1mg, 5mg, 25mg, 50mg and 100mg
ichorbio regularly manufactures multi-gram amounts of our anti-CD40 G28.5 clone – please contact us for pricing.

Mouse IgG1 κ

Tumor necrosis factor receptor superfamily member 5, BP50, CD40L receptor

P27512

Mouse

Mouse

Clone G28.5 recognizes an epitope on human CD40

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) – a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

1.0 mg/ml

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 – 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free

>95% by SDS-PAGE and HPLC

>98% by SDS-PAGE and HPLC

≤ 1.0 EU/mg as determined by the LAL method

≤ 0.75 EU/mg as determined by the LAL method

Aggregation level ≤ 5%

Aggregation level ≤ 1%

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Functional Assays, Flow Cytometry

Each investigator should determine their own optimal working dilution for specific applications.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.